Lilly expands infectious disease portfolio with three strategic acquisitions
Lilly has announced three acquisitions targeting viral and bacterial pathogens associated with significant health risks.
Therapeutic Area
Therapeutic area intelligence for Viral and Bacterial Pathogens with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.